Myeloproliferative neoplasm screening: Difference between revisions
Gerald Chi (talk | contribs) m Gerald Chi moved page Myeloproliferative disease screening to Myeloproliferative neoplasm screening |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myeloproliferative disease}} | {{Myeloproliferative disease}} | ||
{{CMG}} {{AE}} {{MJK}} | |||
==Overview== | |||
Screening for myeloproliferative neoplasm by quantitative cell-based ''JAK2V617F'' mutation assays may be helpful among patients with [[erythrocytosis]], [[thrombocytosis]], splanchnic vein thrombosis, and unexplained BCR-ABL1-negative [[granulocytosis]].<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | |||
==Screening== | |||
Screening for myeloproliferative neoplasm by quantitative cell-based ''JAK2V617F'' mutation assays may be helpful among patients with the following:<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416 }} </ref> | |||
*[[Erythrocytosis]] | |||
*[[Thrombocytosis]] | |||
*Splanchnic vein thrombosis | |||
*Unexplained BCR-ABL1-negative [[granulocytosis]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 21:40, 22 October 2015
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm screening On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm screening |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Screening for myeloproliferative neoplasm by quantitative cell-based JAK2V617F mutation assays may be helpful among patients with erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and unexplained BCR-ABL1-negative granulocytosis.[1]
Screening
Screening for myeloproliferative neoplasm by quantitative cell-based JAK2V617F mutation assays may be helpful among patients with the following:[1]
- Erythrocytosis
- Thrombocytosis
- Splanchnic vein thrombosis
- Unexplained BCR-ABL1-negative granulocytosis
References
- ↑ 1.0 1.1 Tefferi A, Noel P, Hanson CA (2011). "Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology". J Mol Diagn. 13 (5): 461–6. doi:10.1016/j.jmoldx.2011.05.007. PMC 3157620. PMID 21723416.